Lung Cancer - Multimodality Therapy

JANS Article

Clinical Responses to Tarlatamab Among Patients With Pulmonary Carcinoid

September 10, 2026 | Akshay PatelSilver Contributor

In this Memorial Sloan Kettering series, 11 patients with metastatic DLL3-high pulmonary carcinoid received the DLL3/CD3 bispecific T-cell engager tarlatamab. Eight patients (73 percent) achieved an objective response; all had disease control and measurable tumor...

JANS Article

Clinical Responses to Tarlatamab Among Patients With Pulmonary Carcinoid

September 10, 2026 | Akshay PatelSilver Contributor

In this Memorial Sloan Kettering series, 11 patients with metastatic DLL3-high pulmonary carcinoid received the DLL3/CD3 bispecific T-cell engager tarlatamab. Eight patients (73 percent) achieved an objective response; all had...

JANS Article

Surgical Outcomes After Chemotherapy Plus Nivolumab and Chemotherapy Plus Nivolumab and Ipilimumab in Patients With Non-Small Cell Lung Cancer

April 18, 2024 | Mujtaba MubashirGold Contributor

This study reviews 44 patients with stage IB (larger than 4 cm) to IIIA non-small cell lung cancer who were treated on sequential platform arms of the NEOSTAR trial. Twenty-two...

JANS Article

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 10, 2023 | Aristotle ProtopapasGold Commentor

A manuscript that wil certainly be discussed in lung MDT! The thought of a RCT in these earlier stages may be already in the mind of the sponsors… The authors...

JANS Article

Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer

November 9, 2023 | Javeria Tariq

This paper looked at the immunotherapy agent Durvalumab used in the perioperative period for resectable NSCLC. A total of 802 patients were enrolled in the study, of which 400 received...

JANS Article

Survival Following Multimodality Treatment Including Surgery for Stage IA–IIIB Small-Cell Lung Cancer

June 13, 2019 | Claire Vernon

To evaluate the benefit of multimodality treatment for patients with limited disease small-cell lung cancer, Weckler and colleagues retrospectively reviewed outcomes for 47 patients treated at their institution between 1999...

JANS Article

A Year at the Forefront of General Thoracic Surgery

April 17, 2019 | Wei-Guo Ma

Dr Burt gives a brief overview of the considerable advances for patients with thoracic malignancies (non–small cell lung cancer in particular).

...
JANS Article

Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non–Small Cell Lung Cancer

March 4, 2019 | Marco NardiniBronze Contributor

The complete pathologic response rate in this study is revealed to be low, lower than expected after stereotactic ablative radiotherapy (SABR) for early stage non-small cell lung cancer: only 60%....

JANS Article

Aggressive Radiotherapy, Surgery Doubles Overall Survival in Non-Small Cell Lung Cancer With Limited Mets

October 23, 2018 | Mark FergusonBronze Contributor

Forty-nine patients with limited metastatic non-small cell lung cancer (three or fewer metastatic sites) who did not progress on initial systemic therapy were randomized to surgery or RT vs standard...

JANS Article

Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC

September 25, 2018 | Mark FergusonBronze Contributor

This comprises the eagerly anticipated summary of the second primary endpoint of the PACIFIC trial of Durvalumab vs placebo in patients who completed CT/RT without progression for unresectable stage III...

JANS Article

PACIFIC: Time for a Surgical IIIA Uprising

August 20, 2018 | Mark FergusonBronze Contributor

This provocative editorial outlines concepts that thoracic surgeons should understand in the era of immunotherapy for potentially resectable N2 disease.

...
Video

Making Difficult Decisions in Lung Cancer: Oligometastasis, Ground Glass Opacities, Bilateral Lung Lesions, Surgery for Recurrence

July 5, 2018 | Gilbert Massard

Gilbert Massard of the Centre Hospitalier in Strasbourg, France, discusses difficult treatment decisions in lung cancer. He reviews the different treatment approaches for oligometastasis, ground glass opacities, and multiple primary...

JANS Article

Concurrent Versus Sequential Chemoradiation Therapy in Completely Resected Pathologic N2 Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Data Base

April 13, 2018 | Mark FergusonBronze Contributor

The authors found that adjuvent chemoradiotherapy after resection of N2 NSCLC was more effective if given sequentially than concomitantly.

...
LOAD MORE
ADVERTISE ON CTSNET